The use of low-molecular-weight heparin bridging therapy for secondary prevention after an acute stroke is being questioned after new evidence showed increased risks of ischaemic recurrence and intracerebral bleeding. It may be preferable to use direct acting oral anticoagulants (DOACs) that have a rapid onset and are reversible rather than slow-onset vitamin K antagonists such ...
LMWH bridging therapy redundant for stroke patients in DOAC era
By Michael Woodhead
26 Jun 2019